For instance, there is solid evidence that Janus Kinase (JAK1 and JAK2) signaling pathway is crucially involved in the induction and exacerbation of hyperinflammatory syndromes in COVID-19 patients and, in turn, specific JAK inhibitors (e.g., baricitinib and rituxolitinib) may have a particular value in repressing COVID-19 severity [142, 143]. The gene discussed is JAK1; the disease is COVID-19.